Wedbush Initiates Coverage On Ikena Oncology with Outperform Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has initiated coverage on Ikena Oncology (NASDAQ:IKNA) with an Outperform rating and a price target of $11.
September 22, 2023 | 8:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ikena Oncology has been given an Outperform rating by Wedbush, with a price target of $11.
The Outperform rating from Wedbush indicates a positive outlook for Ikena Oncology. The price target of $11 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100